Cellprothera raises €4.4 M
Mulhouse biotech Cellprothera, specializing in cell regeneration, has just raised 4.4 million euros. With this sum, the biotech intends to accelerate its development, and finalize, by the end of the year, the recruitment of patients for its phase I/IIb clinical trial intended to evaluate the safety and the effectiveness of its cells. strains in patients with acute myocardial infarction. In parallel, Cellprothera also hopes to optimize its manufacturing process for the next phases of clinical development and commercialization.
Osivax receives a grant from the Bill & Melinda Gates Foundation
The Bill & Melinda Gates Foundation has just granted a grant, of an unspecified amount, to the Lyon biotech Seed wax. These funds will be used to assess the extent and duration of protection provided by OVX836, the biotech’s influenza vaccine candidate, once morest a wider range of seasonal and highly pathogenic influenza strains. OVX836 is currently undergoing several phase II clinical trials in healthy volunteers.
VOS INDICES
source
Confo Therapeutics s’entend avec Daiichi Sankyo
The Belgian biotech has entered into an agreement with Daiichi Sankyo for the discovery of treatments targeting G protein-coupled receptors. The collaboration aims to develop new small molecules once morest an undisclosed target related to diseases of the central nervous system. Confo might receive a total of 168 M€ in initial payment, milestones (without the distribution having been specified) as well as royalties on the sales of products emerging from the collaboration. A few weeks ago, the Belgian biotech sold the rights to one of its drug candidates to Lilly.
Selected for you
